Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Post-Resection Benefit

This retrospective two-center comparison gives hepatology pharmacists real-world data on two distinct adjuvant strategies after curative hepatocellular carcinoma resection, informing regimen selection when guideline direction is limited.

lenvatinibtislelizumabtranscatheter arterial chemoembolizationTACEhepatocellular carcinomaadjuvant therapyimmune checkpoint inhibitortyrosine kinase inhibitorPD-1liver resectionpropensity score matchingretrospective cohortoncology pharmacy Oncology Pharmacy

Background Information

Adjuvant therapies improve survival in high-risk liver cancer patients.

Hepatocellular carcinoma (HCC) patients at high risk of recurrence need effective adjuvant treatments after liver resection. Both postoperative adjuvant transcatheter arterial chemoembolization (PA-TACE) and lenvatinib plus tislelizumab (PA-LT) groups showed improved recurrence-free survival (RFS) and overall survival (OS) compared to liver resection (LR) alone, with no significant difference between PA-TACE and PA-LT. This study suggests both PA-TACE and PA-LT as effective adjuvant options for improving outcomes in high-risk HCC patients; however, head-to-head comparisons showed no superiority of one over the other. PA-TACE and PA-LT both enhance patient outcomes post-liver resection with no major safety concerns.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Feng X, Ao Y, Wang L, Chen K, Tang C, Huang C

Citation: Feng X, Ao Y, Wang L, et al. Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization versus lenvatinib plus tislelizumab in patients with BCLC stage 0 -B hepatocellular carcinoma after radical resection. Frontiers in immunology. 2026;17:1778330. doi:10.3389/fimmu.2026.1778330

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →